1. Ductal cells of minor salivary glands in Sjögren's syndrome express LINE-1 ORF2p and APOBEC3B
- Author
-
Evangelos Tsiambas, Alexandra Sklavounou, Konstantinos I. Tosios, Galinos Fanourakis, Eleni-Marina Kalogirou, and Evangelia Piperi
- Subjects
Adult ,Male ,0301 basic medicine ,Cancer Research ,Pathology ,medicine.medical_specialty ,Adolescent ,Ductal cells ,Salivary Gland Diseases ,Salivary Glands, Minor ,medicine.disease_cause ,Salivary Glands ,Pathology and Forensic Medicine ,Autoimmunity ,Minor Histocompatibility Antigens ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,stomatognathic system ,Antigen ,Cytidine Deaminase ,medicine ,Deoxyribonuclease I ,Humans ,Epigenetics ,Aged ,biology ,business.industry ,Epithelial Cells ,Middle Aged ,Immunohistochemistry ,Staining ,Sjogren's Syndrome ,030104 developmental biology ,Otorhinolaryngology ,030220 oncology & carcinogenesis ,Salivary Duct Calculi ,biology.protein ,Periodontics ,Female ,Oral Surgery ,Antibody ,business ,Immunostaining - Abstract
Background Type I interferon activation is a hallmark event in Sjogren's syndrome. L1 retroelements stimulate plasmacytoid dendritic cells, activating the type I interferons, and are regulated by various mechanisms, including the APOBEC3 deaminases. As L1s are potential trigger factors in autoimmunity, we aimed to investigate the immunohistochemical localization of L1 ORF2p and its inhibitor APOBEC3B protein in minor salivary glands of Sjogren's syndrome patients. Methods Twenty minor salivary gland-tissue samples from 20 Sjogren's syndrome patients, classified according to Tarpley's histological criteria, and 10 controls were evaluated for L1 ORF2p and APOBEC3B expression via immunohistochemistry. Results L1 ORF2p was expressed in 17/20 SS patients and all controls. APOBEC3B expression was observed in 15/20 Sjogren's syndrome patients, 5/5 chronic sialadenitis, and 3/5 normal minor salivary glands. Both antibodies stained the cytoplasm of the ductal epithelial cells. Negative staining was observed in the acinar cells. L1 ORF2p-positive immunostaining was significantly lower in Tarpley IV Sjogren's syndrome patients than controls (P = .039), and APOBEC3B-positive staining was significantly lower in Tarpley I compared to Tarpley II Sjogren's syndrome patients (P = .008) and controls (P = .035). Conclusions L1 ORF2p and APOBEC3B are expressed in the ductal epithelial cells of minor salivary glands that are among the key targets in Sjogren's syndrome. L1 ORF2p expression may promote the L1 ability to act as an intrinsic antigen in Sjogren's syndrome. The potential future use of L1 ORF2-reverse transcriptase inhibitors in autoimmunity supports further investigation of L1 epigenetic regulation by APOBEC3 enzymes.
- Published
- 2017
- Full Text
- View/download PDF